Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$572,000Cash on Hand
0.5mo Cash Runway
Follow HLSQ by emailGet an email when HLSQ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HLSQ, unsubscribe in one click. Privacy
📣 What HLSQ Says Is Next
by 2030 · “Market expected to reach $37.84 billion by 2030 https://www.grandviewresearch.com/industry-analysis/video-analytics-market $37.84 B $12.71 B 2025 2030 Critical Infrastructure Protection Rail, transportation, industrial, energy, and sensitive sites.”
Company press release, Jun 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 23, 2026 ·
Financing Issued 5,332,617 restricted shares to Mandragola Ltd. in three tranches from October 20 to 23, 2026, via cashless warrant exercises tied to the DFSL acquisition. Shareholders approved raising the 2026 Equity Incentive Plan reserve to 6,000,000 shares. Form 8-K · SEC filing
Oct 13, 2026 ·
Financing Tessera has raised more than $6 million in net proceeds through its at-the-market offering program through October 12, 2026, at an average net price of approximately $1.11 per share, adjusted for a one-for-ten reverse stock split effective September 9, 2026. Management may temporarily halt ATM sales. Form 8-K · SEC filing
Oct 6, 2026 ·
Shareholder vote Stockholders will vote on Oct 20, 2026 on a plan amendment adding 5,315,000 shares, raising the reserve from 685,000 to 6,000,000 post reverse split. A possible adjournment vote is also on the ballot. Form DEF 14A · SEC filing
Oct 5, 2026 ·
Financing Entered a $5,000,000 revolving credit line with Mandragola Ltd., separate from the existing $2,000,000 line, with no amount drawn yet. Advances bear 12% simple interest, mature October 5, 2029, and convert at the lower of the five-day low close and $1.00, capped at 19.99% of shares absent stockholder approval. Form 8-K · SEC filing
Sep 29, 2026 ·
Tessera Defense and Homeland Security set a 2027 revenue target of $14-16 million, weighted to the second half, and targets of about $21 million in 2028 and $30 million in 2029. Management said $7 million is supported by backlog, signed contracts or purchase orders. Form 8-K · SEC filing · Press release
Sep 25, 2026 ·
Deal Tessera Israel, a subsidiary, obtained an option to buy X SE's 51% stake in RT LTA Systems, an Israeli tethered aerostat maker, for $1,000,000 in option consideration due within 30 days. Purchase price is the lower of $13,000,000 and a formula based on 2026-2028 EBITDA and revenue. Form 8-K · SEC filing
Sep 22, 2026 ·
Deal Tessera amended its Sept 16, 2026 agreement to buy a 15% stake in Israeli drone-testing firm M.E.A. Testing Systems for 130,000 shares plus 65,000 more, and extended a loan of up to $475,000 at 12% to the seller. A license agreement with MEA was also signed. Form 8-K · SEC filing
Sep 15, 2026 ·
Listing Company completed a one-for-ten reverse split effective September 9, 2026, then changed its name from BiomX to Tessera Defense and Homeland Security, trading as HLSQ from September 11. Also furnished a CEO letter and investor presentation. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2029 · Phase 1/2 · Recruiting · A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HLSQ holds $572,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.3M/quarter from operations,
an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 0 months +40
ATM program on file since Jul 2026 +15
Shelf registration (S-3, Dec 2023) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Aug 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 26,723,870 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HLSQ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HLSQ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.